915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

首页> 外文期刊>European Journal of Cancer Supplements >915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

【24h】

915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

机译：915海报在晚期卵巢癌的一线治疗中，紫杉醇/卡铂（TC）与紫杉醇/卡铂，然后是拓扑替康（TOP）。 AGO OVAR和GINECO的妇科癌症间研究小组（GCIG）III期临床试验的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. 902 ORAL Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：902口服紫杉醇-卡铂-吉西他滨（TCG）与紫杉醇-卡铂（TC）作为卵巢癌女性的一线治疗：GCIG III组随机研究（AGO-OVAR 9，GINECO-TCG，NSGO-OC-0102）
2. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. [J] . Pfisterer J, Weber B, Reuss A, Journal of the National Cancer Institute . 2006,第15期

机译：拓扑替康在卡铂和紫杉醇一线治疗晚期卵巢癌的一线治疗中的随机III期试验：AGO-OVAR和GINECO的妇科癌症组间试验。
3. 36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco [J] . E.Pujade-Lauraine, J.Pfisterer, A.Lortholary, European Journal of Cancer Supplements . 2003,第5期

机译：36紫杉醇/卡铂（TC）vs紫杉醇/卡铂（随后是托泊替康（TC-Top））用于卵巢癌Flgo IIB – IV期一线治疗卵巢癌研究小组III期妇产科卵巢癌研究的中期结果和Gineco
4. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients [O] . U Wagner, C Marth, R Largillier, 2012

机译：聚乙二醇化脂质体阿霉素和卡铂与紫杉醇和卡铂在铂敏感型卵巢癌患者中进行的III期GCIG CALYPSO试验的最终总体生存结果
5. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel [O] . P. Hoskins, I. Vergote, A. Cervantes, 2010

机译：先进的卵巢癌：III期随机研究顺铂 - 拓扑替替康和卡铂 - 紫杉醇与Carboplatin-PACLitaxel

915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

著录项

相似文献

相关主题

期刊订阅